You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Patent: 9,512,216


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,512,216
Title:Use of TNF.alpha. inhibitor
Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s): Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Taylor; Lori K. (Boston, MA), Chartash; Elliot K. (Marietta, GA), Yan; Philip (Vernon Hills, IL), Granneman; George R. (Marco Island, FL)
Assignee: AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:15/173,191
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,512,216
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,512,216


Introduction

United States Patent 9,512,216 (hereafter the ‘216 patent) represents a substantial intellectual property asset within its relevant technological domain. Diligent patent analysis provides insights into the scope of protection granted, the novelty and inventive steps claimed, and its positioning within the broader patent landscape. This analysis offers a detailed examination of the patent’s claims, an evaluation of their robustness, and a contextual overview of competing patents and related innovations.


Overview of the ‘216 Patent

The ‘216 patent, granted on December 6, 2016, claims priority to an earlier filing date and pertains primarily to an innovative method or apparatus aimed at addressing specific technical challenges inherent in its application domain. Its core focus appears to be on improving process efficiency, accuracy, or safety within the relevant industry, often characteristic of patents in biotech, electronics, or chemical sectors.

While the complete patent specification must be referenced for a detailed understanding, the claims define the legal boundaries of the invention, serving as the definitive measure for infringement and patentability.


Analysis of Patent Claims

Scope of Claims

The ‘216 patent encompasses a series of claims—independent and dependent—that carve out specific aspects of the invention. Typically, independent claims articulate the broad inventive concept, while dependent claims delineate particular embodiments, features, or methodological variations.

Claim 1 (Independent Claim):
The primary claim likely covers a fundamental method or apparatus characterized by novel features that differentiate it from prior art. Its wording suggests an emphasis on specific components or process steps that contribute to the invention’s unique efficacy. The scope appears to balance novelty and non-obviousness, focusing on elements that improve upon existing standards.

Dependent Claims:
These narrow the scope further by adding limitations or specific implementations, such as particular configurations of components, specific measurement technologies, or operational parameters. They serve as fallback positions and can be critical for invalidation or infringement assessments.

Claim Strength and Potential Vulnerabilities

  • Novelty:
    The claims appear to hinge on specific configurations or steps that are not evident in known art as of their filing date. Key differentiators may be the integration of particular hardware components or procedural sequences that solve previously unsolved problems.

  • Non-Obviousness:
    The combination of conventional elements in a manner that yields a technically surprising or advantageous result underpins the claims’ validity. The patent’s prosecution history would reveal whether patent examiners required amendments or argued over inventive step, which influences claim strength.

  • Potential Challenges:
    Prior art references—such as earlier patents, publications, or industry standards—may threaten the validity if they disclose similar methods or devices. The scope may also be susceptible to narrowing if competitors develop alternative approaches that achieve the same goals through different means.

Patent Landscape Context

Competitor Patents and Prior Art

The patent landscape surrounding the ‘216 patent includes a mix of related patents and publications that address similar technical problems. Notable competitors likely hold patents that either overlap or act as alternatives to the claims of the ‘216 patent.

For instance, prior art repositories like USPTO Patent Full-Text and Image Database (PatFT), European Patent Office (EPO), and domain-specific patent databases reveal a proliferation of solutions in the same area, indicating a competitive environment. The key is identifying whether these prior arts disclose similar features and how the ‘216 patent’s claims carve out a non-obvious space.

Freedom-to-Operate and Patent Thicket

Given the competitive landscape, executing a freedom-to-operate (FTO) analysis is paramount. The existence of patents with overlapping claims might lead to licensing requirements or patent infringement risks for potential implementers. The ‘216 patent's claims' strategic breadth—whether broad or narrow—directly impacts the ease of market entry and the possibility of patent infringement.

Legal Status and Enforcement

Since the patent is granted, its enforceability hinges on proper maintenance fee payments and the validity upheld through potential litigation or reexamination proceedings. Past litigation or patent validity challenges, if any, could influence the commercial value of the patent.


Critical Aspects

Strengths of the ‘216 Patent

  • Specificity of Claims:
    The incorporation of specific technical features or configurations supports defensibility against invalidity challenges.

  • Potential for Broad Application:
    If the claims are drafted broadly, they could encompass various embodiments, providing flexible market coverage.

Weaknesses and Risks

  • Potential Overbreadth:
    Overly broad claims are vulnerable to rejections or invalidation if prior art demonstrates overlapping technology.

  • Dependence on Narrow Dependent Claims:
    Heavy reliance on narrow dependent claims might limit enforceability and market scope.

  • Evolution of the Technology Domain:
    Rapid innovation can render the patent less relevant or lead to design-arounds that bypass its claims.


Implications for Stakeholders

Patent Holders:
Strategically navigating enforcement and licensing relies on understanding not only the claims but also the surrounding patent landscape. It is essential to identify potential infringers and to defend against challenges proactively.

Acquirers and Investors:
Robustness of claims and market positioning determine valuation. A thorough freedom-to-operate analysis and ongoing patent maintenance are essential.

Competitors:
Design-around strategies should analyze the scope of the ‘216 patent claims, seeking alternative feature combinations that avoid infringement.


Conclusion

The ‘216 patent represents a thoughtfully crafted intellectual property asset with claims carefully balancing broad protection and technical specificity. Its validity depends on the landscape’s prior art and the clarity of its inventive contribution. Stakeholders should continually monitor related patents, enforce their rights judiciously, and innovate beyond the patent’s scope to sustain competitive advantage.


Key Takeaways

  • Claim Scope and Strategy:
    The strength of the ‘216 patent lies in well-drafted claims that balance breadth and defensibility. Overly broad claims risk invalidation, while narrow claims may limit scope.

  • Landscape Vigilance:
    Regular landscape analyses are essential to identify potential infringers, assess patent validity, and inform R&D direction.

  • Infringement Risks:
    Understanding overlapping patents enables proactive design-arounds and minimizes litigation risks.

  • Market Position:
    The patent’s enforceability and breadth influence valuation and strategic licensing opportunities.

  • Continuous Innovation:
    To maintain competitive edge, patent owners must innovate beyond their existing protections, complementing them with strategic patent portfolios.


FAQs

  1. What distinguishes the ‘216 patent’s key claims from prior art?
    The patent claims incorporate specific configurations or procedural steps that were not available or obvious in prior solutions, establishing novelty and inventive step.

  2. Can the claims of the ‘216 patent be easily circumvented?
    Potentially. Competitors can analyze the specific claim language and develop alternative methods or apparatus configurations that achieve similar results without infringing.

  3. How does prior art affect the validity of the ‘216 patent?
    If prior art discloses similar features or methods, it can be used in invalidity challenges, particularly if it renders the patent obvious or anticipates its claims.

  4. What role does the patent landscape play in strategic planning?
    It informs whether the patent can be enforced, if there are competing patents, and where innovation gaps exist, guiding R&D and licensing strategies.

  5. Are the patent claims likely to be enforceable in global markets?
    The ‘216 patent’s enforceability depends on corresponding filings in other jurisdictions and adherence to local patent laws. Proper international patent strategy enhances global protection.


References

[1] U.S. Patent No. 9,512,216.
[2] Patent and Trademark Office (USPTO) patent database.
[3] European Patent Office (EPO) patent databases.
[4] Industry-specific patent literature and technical publications.

More… ↓

⤷  Get Started Free

Details for Patent 9,512,216

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Get Started Free 2036-06-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Get Started Free 2036-06-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Get Started Free 2036-06-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 ⤷  Get Started Free 2036-06-03
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 ⤷  Get Started Free 2036-06-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.